Trial Profile
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Risedronic acid
- Indications Osteoporosis; Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms FACT; FACT-International
- Sponsors Merck Sharp & Dohme; Organon
- 04 Oct 2005 New trial record.